{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Oblimersen_Sodium",
  "nciThesaurus": {
    "casRegistry": "190977-41-4",
    "chebiId": "",
    "chemicalFormula": "C172H204N62O91P17S17.17Na",
    "definition": "The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.",
    "fdaUniiCode": "SH55B0RQ9K",
    "identifier": "C66722",
    "preferredName": "Oblimersen Sodium",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1291"
    ],
    "synonyms": [
      "Anticode G3139",
      "Augmerosen",
      "BCL-2 Antisense Oligodeoxynucleotide G3139",
      "BCL-2 Antisense/G3139",
      "G3139",
      "G3139 Antisense Oligonucleotide",
      "G3139 BCL-2 Antisense Oligo",
      "G3139 BCL-2 Antisense Oligodeoxynucleotide",
      "G3139 BCL-2 Antisense Oligonucleotide",
      "Genasense",
      "OBLIMERSEN SODIUM",
      "Oblimersen Sodium",
      "augmerosen",
      "bcl-2 antisense oligodeoxynucleotide G3139",
      "oblimersen sodium"
    ]
  }
}